NCT00830024View on ClinicalTrials.gov

Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Non-fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

June 30, 2005

Study Completion Date

June 30, 2005

Conditions
Healthy
Interventions
DRUG

Alprazolam Extended-Release 3 mg Tablets

1 x 3 mg, single dose non-fasting

DRUG

Alprazolam Extended-Release 3 mg Tablets

1 x 3 mg, single dose non-fasting

Trial Locations (2)

56721

PRACS Institute, Ltd., East Grand Forks

58104

PRACS Institute, Ltd., Fargo

All Listed Sponsors
lead

Teva Pharmaceuticals USA

INDUSTRY